Effect of Oral Supplementation With Probiotics

Obesity Clinical Trial

Official title:

Effect of Oral Supplementation With Probiotics on Cardiometabolic Risk Factors, Microflora and Intestinal Epithelial Permeability, Mineral Content and Lifestyle in Obese Women With Postmenopausal Metabolic Syndrome: Double-blind, Randomized Clinical Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03100162
• Other study ID #: 871/15
• Status: Completed
• Phase: N/A
• Start date: February 27, 2016
• Est. completion date: February 2, 2018

Study information

• Verified date: May 2020
• Source: Poznan University of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Effect of oral supplementation with probiotics on cardiometabolic risk factors, microflora and intestinal epithelial permeability, mineral content and lifestyle in obese women with postmenopausal metabolic syndrome: double-blind, randomized clinical trial.

Description:

The purpose of the study is to determine whether oral probiotic supplementation affects cardiometabolic risk, intestinal epithelial permeability, metabolic activity and intestinal flora composition, mineral content, and lifestyle in obese women with metabolic syndrome.

Probiotics are a group of non-pathogenic microbes that bring health benefits to the host. Their use enables the variety and proper functioning of intestinal microflora. The use of probiotics increases the amount of bifidobacteria and lactobacilli, what directly affects the reduction of endotoxemia by sealing the intestinal wall, as well as the improvement of fat, carbohydrate and insulin metabolism.

The project is due to evaluate the effect of supplementation with selected probiotics in patients with metabolic syndrome on:

• lipid metabolism- total cholesterol, HDL and LDL cholesterol and triglycerides,

• blood glucose concentration,

• blood pressure values,

• anthropometric parameters,

• quality of life,

• the contentl of minerals,

Recruitment information / eligibility

• Status: Completed
• Enrollment: 81
• Est. completion date: February 2, 2018
• Est. primary completion date: January 4, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 45 Years to 70 Years

Eligibility

Inclusion Criteria:

• body mass index (BMI) equal to or greater than 30 kg/m2

• age 45 to 70 years

• stable body weight (< 3 kg self-reported change during the previous three months)

• written informed consent to participate in the study,

• > = 1 year after the last menstrual period;

• abdominal obesity - waist circumference> 80 cm;

• body fat content measured by bio-impedance = 33%;

Exclusion Criteria:

• secondary obesity or secondary hypertension

• diabetes type I

• gastrointestinal disease;

• dyslipidaemia, type 2 diabetes, hypertension requiring the implementation of pharmacological treatment in the last 3 months prior to observation or follow-up;

• a history of use of any dietary supplements within the one month prior to the study

• taking antibiotics within 1 month before starting the study;

• Clinically relevant acute or chronic inflammatory disease in the respiratory, gastrointestinal or genitourinary system or in the mouth, throat, paranasal sinuses and / or connective tissue disease, arthritis;

• simultaneous participation in a study that affects weight change or use of diet / medication / nutritional behaviors affecting body weight changes;

• consumption of pre- and probiotic-enriched products (for at least 3 weeks prior to the first screening visit) and products with high fiber content or large amounts of fermented foods (> 400g / day);

• hormone replacement therapy;

• a history of infection in the month prior to the study

• nicotine, drug or alcohol abuse

• vegetarian diet;

• or other condition that, in the opinion of the investigators, would make participation not in the best interest of the patient or could prevent, limit, or confound the study results

Related Conditions & MeSH terms

• Metabolic Syndrome
• Obesity

Intervention

Dietary Supplement:
• Probiotic

• Placebo

Locations

Country	Name	City	State
Poland	Department of Education and Obesity Treatment and Metabolic Disorders, Poznan University of Medical Sciences	Poznan

Sponsors (3)

Lead Sponsor	Collaborator
Poznan University of Medical Sciences	German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Poznan University of Life Sciences

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with decreased cardiometabolic risk	Cardiometabolic risk will be estimated at baseline and after 3 months of treatment using the SCORE scale. SCORE scale summarize 5 risk factors (sex, age, systolic blood pressure, total cholesterol and smoking). The number of patients with decreased cardiometabolic risk will be measured.	At the baseline and after 3 months of treatment
Secondary	blood pressure		At the baseline and following 3 months of treatment
Secondary	Body mass index		At the baseline and following 3 months of treatment
Secondary	waist circumference		At the baseline and following 3 months of treatment
Secondary	serum lipids		At the baseline and following 3 months of treatment
Secondary	Total antioxidant status (TAS) evaluated by colorimetric method with Tas Randox kit		At the baseline and following 3 months of treatment
Secondary	insulin estimated by immunoassay (DIAsource immunoassays)		At the baseline and following 3 months of treatment
Secondary	interleukin-6 measured by an enzyme-linked immunosorbent assay (R&D Quantikine® Human Il-6 kit)		At the baseline and following 3 months of treatment
Secondary	Total body fat content	Total body fat content will be measured at baseline and after 3 months of treatment using electrical bioimpedance	At the baseline and following 3 months of treatment
Secondary	Measurement of mineral content in hair	The content of iron, magnezium, calcium, selenium, copper and lead in patients' hair at baseline and after 3 months of treatment will be estimated using atomic absorption spectrometry.	At the baseline and following 3 months of treatment
Secondary	Fecal examination (Kalprotektyna, Alfa1 - antytrypsyna )		At the baseline and following 3 months of treatment
Secondary	Quality of life	"The World Health Organization Quality of Life (WHOQOL) - BREF"	At the baseline and following 3 months of treatment